topotecan/кровотечение

Ссылка сохраняется в буфер обмена

Выберите тип сортировки

Страница 1 от 43 полученные результаты

Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

BACKGROUND The objectives of this study were to determine the maximum tolerable dose (MTD), toxicity, efficacy, and feasibility of a sequential regimen of fixed-dose topotecan (1.00 mg/m2 on Days 1-5) and increasing doses of oral etoposide (50 mg, 75 mg, and 100 mg on Days 6-12 or Days 6-19) in

Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

OBJECTIVE We used high-dose cyclophosphamide plus topotecan/vincristine (CTV) or irinotecan (C/I) in patients with resistant neuroblastoma. The aim was to use a regimen with little risk to major organs to (a) achieve or consolidate remission in heavily treated patients and to (b) induce an

Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

OBJECTIVE We conducted a phase I trial of the injectable formulation of topotecan given orally once daily for 5 days for 2 consecutive weeks (qd x 5 x 2) in pediatric patients with refractory solid tumors. METHODS Cohorts of two to six patients received oral topotecan at 0.8, 1.1, 1.4, 1.8, and 2.3

Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

BACKGROUND Topotecan is an active agent for the management of untreated and recurrent extensive-disease small cell lung cancer (ED-SCLC). This study was designed to evaluate the efficacy and safety of a triplet combination with topotecan added to the standard PE regimen in previously untreated

Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

OBJECTIVE Combined cisplatin-topotecan therapy is standard care for advanced cervical cancer, however it is associated with haematotoxicity and nephrotoxicity. This trial was designed to assess the combination of carboplatin which is less nephrotoxic, and oral topotecan. METHODS Patients with

Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

OBJECTIVE The aim of this trial was to investigate the efficacy and toxicity of a relative high-dose of topotecan combined with carboplatin in recurrent or persistent epithelial ovarian cancer (EOC). METHODS Patients participating in this phase II trial received topotecan at a dose of 1.0

Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

OBJECTIVE Development of new therapies for previously treated small-cell lung cancer (SCLC) is a major unmet need. Here, we describe a randomized, phase II trial of weekly topotecan with or without ziv-aflibercept (VEGF-trap) in this clinical setting. METHODS Patients with previously treated SCLC

Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

BACKGROUND The Cancer and Leukemia Group B evaluated oral topotecan administered at 2 schedules and doses for myelodysplastic syndrome (MDS). METHODS Patients with previously untreated primary or therapy-related MDS were eligible. Patients with refractory anemia (RA), RA with ringed sideroblasts, or

Intraocular hemorrhage after intra-arterial chemotherapy for retinoblastoma in sickle cell trait.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Massive intraocular hemorrhage developed in a child with advanced unilateral retinoblastoma after intrarterial treatment with Melphalan and Topotecan. The child tested positive for sickle cell trait. Sickle cell trait may predispose such children to slower vascular transit time, hypoxia, sickling

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

BACKGROUND This phase I study evaluated the safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics of two dosing schedules of oral topotecan in combination with pazopanib in patients with advanced solid tumours. METHODS Stage I of this study was to determine whether there was an

Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

BACKGROUND [corrected] Chemotherapeutic agents are playing an increasing role in the management of urothelial carcinoma. Despite recent advances in the treatment of this disease there continues to be a need to identify new active agents and their toxicity spectra. Topotecan is an agent as yet

An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

BACKGROUND The number of effective cytotoxic agents for the treatment of patients with metastatic soft tissue sarcoma (STS) is limited, especially when patients have failed anthracyline-based chemotherapy. METHODS Between 1999 and 2000 a total of 16 patients with histologically proven STS

Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

BACKGROUND The current Phase II study was conducted to evaluate the survival and toxicity observed in children with newly diagnosed brainstem gliomas who were treated with the daily radiotherapy with topotecan used as a radiosensitizer. METHODS Eligible patients were those ages 3-18 years with

Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

The purpose of this study was to determine the activity of topotecan given by 21-day continuous infusion in patients previously treated with one prior therapy for a diffuse large-cell lymphoma or immunoblastic lymphoma. Patients with appropriate histology and measurable disease who had been treated

Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

OBJECTIVE To determine the clinical activity and the toxicity profile of the topoisomerase-I inhibitor, topotecan, in women with recurrent or advanced endometrial carcinoma. METHODS A prospective, phase II clinical trial was initiated by the Eastern Cooperative Oncology Group (ECOG). Patients had

Присоединяйтесь к нашей
странице facebook

Herbal & Natural Medicine

Самая полная база данных о лекарственных травах, подтвержденная наукой

Работает на 55 языках
Травяные лекарства, подтвержденные наукой
Распознавание трав по изображению
Интерактивная карта GPS - отметьте травы на месте (скоро)
Прочтите научные публикации, связанные с вашим поиском
Ищите лекарственные травы по их действию
Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов

Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.